On Wednesday, November 30th – Thursday, December 1st, Guidepoint Insights will be hosting a series of in-person events featuring KOLs who will dive deeper into the Clinical Trials on Alzheimer’s Disease (CTAD) data updates with discussion on the pivotal lecanemab and gantenerumab data sets.


Venue: Ula Restaurant, The Peacock Room, 450 Post St, San Francisco, CA 94102


To request access to CTAD group meetings, complete the form below:


    Wednesday, November 30th

    12:00 PM ET (9:00 AM PT) - Lei Liu

    • Asisstant Professor of Neurology at Harvard Medical School

    1:00 PM ET (10:00 AM PT) - Paul Solomon

    • Visiting Professor of Neurology at Boston University School of Medicine

    2:00 PM ET (11:00 AM PT) - John Hardy

    • Chair of the Molecular Biology of Neurological Disease at University College London

    3:00 PM ET (12:00 PM PT) - Jeffrey Apter

    • President and Medical Director at Global Medical Institutes LLC

    Thursday, December 1st

    1:00 PM ET (10:00 AM PT) - Kinga Szigeti

    • Director, Center of Excellence for Alzheimer's Disease at University at Buffalo

    2:00 PM ET (11:00 AM PT) - Lon Schneider

    • Professor; Director of the USC California Alzheimer's Disease Center and Clinical Center and the clinical core of the USC NIA Alzheimer's Disease Research Center at Keck School of Medicine of USC

    3:00 PM ET (12:00 PM PT) - Frank Tarazi

    • President at CNS Consulting

    4:00 PM ET (1:00 PM PT) - Anton Porsteinsson

    • Professor at University of Rochester Medical Center


    CTAD group meetings will be 50 minutes long and are available only to in-person attendees. Group meetings are not recorded and transcripts will not be available after the event.